Why is Astrazeneca Phar falling/rising?

As of 18-Sep, Astrazeneca Pharma India Ltd is experiencing a decline in its stock price, currently at 9,090.00, which reflects a decrease of 15.0 or 0.16%. Today's price summary indicates that the stock has underperformed its sector by 1.21% and has fallen after two consecutive days of gains. Despite this recent dip, Astrazeneca has shown strong performance over the past month with a 7.83% increase and an impressive 35.91% return over the last year. The company has demonstrated high management efficiency with a return on equity of 20.57% and a low debt-to-equity ratio, contributing to its positive results over the last three quarters, including significant growth in profit after tax and net sales.
In the broader market context, Astrazeneca's short-term performance of 0.12% over the past week is notably lower than the Sensex's increase of 1.80%, indicating a relative underperformance. However, the stock has outperformed the benchmark over longer periods, such as a 23.93% year-to-date return compared to the Sensex's 6.24%. The rising investor participation, as evidenced by a 28.23% increase in delivery volume, suggests ongoing interest in the stock despite its recent price decline. Overall, while Astrazeneca has shown strong fundamentals and consistent returns, its current price movement reflects a temporary setback in the context of broader market trends.